Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities

Neuropathology

Volumn 38, Issue 6, 2018, Pages 646-652

  Khosa, Shaweta ^a   Khanlou, Negar ^b   Khosa, Gurveer S ^c   Mishra, Shri K ^d  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIRA GANDHI MEDICAL COLLEGE   (India)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

chloroquine; hydroxychloroquine; myopathies; toxicity; vacuolar myopathy

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; GLYCOGEN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; OXIDOREDUCTASE; PREDNISONE; ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; CASE REPORT; CELL VACUOLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MONITORING; DRUG WITHDRAWAL; ELECTROMYOGRAM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; MIDDLE AGED; MUSCLE BIOPSY; MYOPATHY; POLYMYOSITIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; SJOEGREN SYNDROME; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; VASTUS LATERALIS MUSCLE; AUTOIMMUNE DISEASE; AUTOPHAGY; CHEMICALLY INDUCED; DRUG EFFECT; MITOCHONDRION; MUSCLE DISEASE; PATHOLOGY;

AGED; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; AUTOPHAGY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; MITOCHONDRIA; MUSCULAR DISEASES;

EID: 85056160102     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12520     Document Type: Article

References (31)

1. Sullivan DJ Jr, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A 1996; 93: 11865–11870.
2. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762–784.
3. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010; 69: 20–28.
4. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: Emerging evidence supporting multiple beneficial effects. Intern Med J 2012; 42: 968–978.
5. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23: 82–91.
6. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: Re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011; 23: 278–281.
7. Abraham R, Hendy R. Effects of chronic chloroquine treatment on lysosomes of rat liver cells. Exp Mol Pathol 1970; 12: 148–159.
8. Whisnant JP, Espinosa RE, Kierland RR, Lambert EH. Chloroquine neuromyopathy. Proc Staff Meet Mayo Clin 1963; 38: 501–513.
9. Eadie MJ, Ferrier TM. Chloroquine myopathy. J Neurol Neurosurg Psychiatry 1966; 29: 331–337.
10. Rewcastle NB, Humphrey JG. Vacuolar myopathy: Clinical, histochemical, and microscopic study. Arch Neurol 1965; 12: 570–582.
11. Mastaglia FL, Papadimitriou JM, Dawkins RL, Beveridge B. Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle. J Neurol Sci 1977; 34: 315–328.
12. Neville HE, Maunder-Sewry CA, McDougall J, Sewell JR, Dubowitz V. Chloroquine-induced cytosomes with curvilinear profiles in muscle. Muscle Nerve 1979; 2: 376–381.
13. Gerard JM, Stoupel N, Collier A, Flament-Durand J. Morphologic study of a neuromyopathy caused by prolonged chloroquine treatment. Eur Neurol 1973; 9: 363–379.
14. Siddiqui AK, Huberfeld SI, Weidenheim KM, Einberg KR, Efferen LS. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 2007; 131: 588–590.
15. Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008; 38: 1206–1210.
16. Scherbel AL. Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: Historic and therapeutic perspectives. Am J Med 1983; 75: 1–4.
17. Stauber WT, Hedge AM, Trout JJ, Schottelius BA. Inhibition of lysosomal function in red and white skeletal muscles by chloroquine. Exp Neurol 1981; 71: 295–306.
18. Estes ML, Ewing-Wilson D, Chou SM et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987; 82: 447–455.
19. Posada C, Garcia-Cruz A, Garcia-Doval I, Millan BS, Teijeira S. Chloroquine-induced myopathy. Lupus 2011; 20: 773–774.
20. Casado E, Gratacos J, Tolosa C et al. Antimalarial myopathy: An underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006; 65: 385–390.
21. Lonesky TA, Kreuter JD, Wortmann RL, Rhodes CH. Hydroxychloroquine and colchicine induced myopathy. J Rheumatol 2009; 36: 2617–2618.
22. Al-Bari MA. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 2015; 70: 1608–1621.
23. Uzar E, Ozay R, Evliyaoglu O et al. Hydroxycloroquine-induced oxidative stress on sciatic nerve and muscle tissue of rats: A stereological and biochemical study. Hum Exp Toxicol 2012; 31: 1066–1073.
24. Clark DW, Strandell J. Myopathy including polymyositis: A likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 2006; 62: 473–479.
25. Pearson CM, Yamazaki JN. Vacuolar myopathy in systemic lupus erythematosus. Am J Clin Pathol 1958; 29: 455–463.
26. Khoo T, Otto S, Smith C et al. Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. Clin Rheumatol 2017; 36: 689–693.
27. Soong TR, Barouch LA, Champion HC, Wigley FM, Halushka MK. New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. Hum Pathol 2007; 38: 1858–1863.
28. Tandler B, Dunlap M, Hoppel CL, Hassan M. Giant mitochondria in a cardiomyopathic heart. Ultrastruct Pathol 2002; 26: 177–183.
29. Kraus B, Cain H. Giant mitochondria in the human myocardium--morphogenesis and fate. Virchows Arch B Cell Pathol Incl Mol Pathol 1980; 33: 77–89.
30. Arbustini E, Diegoli M, Fasani R et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol 1998; 153: 1501–1510.
31. Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 1995; 34: 166–170.